Tongluo Mingmu capsules | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Medicine type: Traditional Chinese medicine
Therapeutic area: Ophthalmology
Indications recorded in the public source: In traditional Chinese medicine (TCM), disperses blood stasis and unblocks the channels, replenishes qi and nourishes yin, and stops bleeding and improves vision. For moderate nonproliferative diabetic retinopathy caused by type 2 diabetes with the TCM pattern of blood stasis obstructing the channels and deficiency of both qi and yin. Manifestations include punctate or patchy retinal hemorrhage, dry eyes, a dull complexion, fatigue and weakness; a pale tongue, or a dark-red tongue with scant fluid, or ecchymoses or petechiae; and a fine, fine-rapid or choppy pulse.
Indication source and scope: Source date(s): 2026-10-23. Manufacturer prescribing information for Mainland China. The revision date could not be confirmed from the original file.
Prescribing-information limitations: Complete official prescribing information obtained. Mainland China label.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Included in national insurance (Category B)
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: Restricted to nonproliferative retinopathy in type 2 diabetes.
Insurance period: 2025-01-01 to 2026-12-31
Insurance verification notes: Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions